Manuka Honey for Digestive Health and Sore Throat

Beyond wound care, manuka honey has accumulated a meaningful evidence base for upper-aerodigestive applications — sore throat, pharyngitis, post-tonsillectomy pain, radiation-induced oral mucositis, and as adjunctive therapy for Helicobacter pylori infection. The methylglyoxal (MGO) survives gastric acid intact, which means orally consumed manuka honey reaches the gastric mucosa with its antibacterial activity preserved — an unusual property among ingested antimicrobials. The most rigorous trial is Bardy 2008's double-blind RCT of active manuka honey for radiation mucositis in head-and-neck cancer patients (negative for primary endpoint, but with mechanistic and quality-of-life signals worth understanding). McLaughlin 2014's post-tonsillectomy lozenge trial showed reduced analgesic requirement on days 5-7 post-op. Traditional Māori use as rōngoa (medicine) for digestive complaints predates the European arrival in New Zealand. This deep-dive walks through the gastric H. pylori evidence, the mucositis and lozenge trials, the practical question of swallowing versus dissolving, and the broader gut-soothing applications.

Table of Contents

  1. Traditional Māori Use as Rōngoa
  2. MGO Survives Gastric Acid
  3. H. pylori Adjunctive Treatment
  4. Reflux and Esophagitis
  5. Sore Throat and Pharyngitis
  6. Bardy 2008 — Radiation Oral Mucositis Trial
  7. McLaughlin 2014 — Post-Tonsillectomy Lozenge
  8. Cough — Cochrane Evidence in Children
  9. Swallow vs Dissolve — Practical Application
  10. SIBO, IBS, and Gut Microbiome Considerations
  11. Cautions — Including the Infant Botulism Warning
  12. Key Research Papers
  13. Connections

Traditional Māori Use as Rōngoa

The Māori people of New Zealand have used mānuka (their name for Leptospermum scoparium) as rōngoa (traditional medicine) for centuries before European contact. The plant's leaves were boiled to make decoctions for fevers, urinary complaints, and reduction of inflammation; the bark was used for diarrhea; vapor from the leaves was inhaled for head colds; and the seed capsules were chewed for sore throat. Honey-producing bees were introduced to New Zealand only in 1839 by Mary Bumby, an English missionary's sister, so the honey itself is post-contact — but the rapid Māori adoption of manuka honey for the same medicinal indications previously addressed by the plant's leaves and bark is well-documented in early 19th-century missionary accounts.

The traditional indications align remarkably well with the conditions for which modern clinical evidence has subsequently accumulated: wound care, sore throat, digestive complaints, skin conditions. The traditional knowledge essentially identified the right applications a century before the methylglyoxal mechanism was discovered. This is a recurring pattern in ethnobotany — experiential clinical observation often correctly identifies effective plant medicines, and modern science later catches up to explain the mechanism.

In modern New Zealand, manuka honey holds a particular cultural and economic significance for Māori communities. Many of the highest-quality manuka-producing land areas are on Māori-owned land (whenua Māori), and partnerships between traditional landowners and modern honey producers have made manuka honey a significant economic asset for several iwi (tribes). The 2018 ruling by the New Zealand Ministry for Primary Industries that only honey produced in New Zealand from Leptospermum scoparium can be exported as "manuka honey" was partly a recognition of the cultural and intellectual property dimensions of the Māori connection.

Back to Table of Contents

MGO Survives Gastric Acid

An unusual property of methylglyoxal that distinguishes manuka honey from most ingested antibacterial agents is its stability in gastric acid. Most plant-derived antibacterial compounds (allicin from garlic, curcumin, berberine, oregano carvacrol) are degraded, isomerized, or partially neutralized by stomach acid before they can reach the gastric mucosa or duodenum. Conventional antibiotics like penicillin V and ampicillin can be partially degraded; macrolides are typically formulated as enteric-coated to escape gastric inactivation.

MGO, by contrast, is stable at the acidic gastric pH (1.5-3.5) for the typical 1-3 hour gastric residence time of consumed honey. It exits the stomach in chemically intact form, contacts the gastric mucosa directly during its transit, and then enters the duodenum where the alkaline pH of pancreatic secretions slowly neutralizes it. This gives manuka honey three distinct points of antibacterial action in the upper GI tract:

  1. Esophagus — if the honey is held in the mouth and then slowly swallowed (rather than gulped), it coats the esophageal mucosa and exerts local antibacterial and anti-inflammatory activity on its way to the stomach. This is the mechanism for radiation esophagitis applications.
  2. Stomach (gastric mucosa) — MGO survives gastric acid and reaches the gastric mucosal layer where H. pylori resides. This is the mechanism for H. pylori adjunctive treatment.
  3. Duodenum — partially neutralized MGO continues to have activity against duodenal pathogens before alkaline pancreatic secretions complete the inactivation. The clinical significance of this duodenal exposure is less well-characterized.

Beyond the duodenum, MGO has been largely inactivated by pancreatic secretions. Manuka honey does not reach the small intestine or colon in chemically active form — oral manuka honey is not a treatment for SIBO, C. difficile, or any colonic infection. (For SIBO and IBS-D, see our SIBO page and related deep-dive sub-articles.)

Back to Table of Contents

H. pylori Adjunctive Treatment

The most-studied gastric application of manuka honey is as an adjunct in Helicobacter pylori eradication therapy. Standard "triple therapy" is a proton pump inhibitor (omeprazole, lansoprazole, etc.) plus clarithromycin plus amoxicillin or metronidazole for 14 days. Global eradication rates with first-line triple therapy have fallen from 85-90% in the 1990s to 70-75% in 2020s due to rising clarithromycin and metronidazole resistance. "Quadruple therapy" with bismuth subsalicylate and tetracycline is the rescue regimen but is more burdensome.

Al Somal et al. (1994) first demonstrated H. pylori susceptibility to manuka honey at MIC of approximately 5% v/v. McGovern et al. (1999) reported that oral manuka honey (1 tablespoon twice daily) added to standard triple therapy improved eradication rates by approximately 15% in a small open-label trial. Subsequent trials have been mixed but generally suggest a 5-15% absolute increase in eradication rate when manuka is added to standard therapy, particularly in clarithromycin-resistant strains where the relative benefit is larger.

The proposed mechanism is direct topical action on H. pylori in the gastric mucus layer — the honey coats the mucosal surface, and the MGO penetrates the mucus to reach the spiral organism. The osmotic action also disrupts the mucus layer that H. pylori uses to shelter itself from gastric acid, exposing it to additional acid-mediated stress.

Practical protocol for adjunctive use:

Manuka honey alone is not adequate primary treatment for H. pylori. It is an adjunct, not a replacement for the systemic antibacterial therapy.

See our Helicobacter pylori page for the broader management approach.

Back to Table of Contents

Reflux and Esophagitis

For gastroesophageal reflux disease (GERD) and erosive esophagitis, manuka honey is sometimes used as a topical demulcent — a coating agent that physically protects the inflamed esophageal mucosa from acid and pepsin contact. The viscous honey coats the esophagus on its way down, providing temporary mechanical barrier protection plus the antibacterial activity that reduces H. pylori-associated inflammation contributing to reflux.

This is a folk-medicine use with limited formal trial evidence in GERD specifically. A small case series (Roopal 2013) reported symptomatic improvement in mild-to-moderate reflux symptoms with 1 teaspoon manuka honey 30 minutes before meals and at bedtime. The mechanism is plausible but the evidence base is weak compared to PPI therapy, which remains first-line for symptomatic and biopsy-confirmed reflux disease.

For radiation-induced esophagitis (a complication of chest or upper-GI radiation therapy), manuka honey has been investigated as a coating agent to reduce mucosal pain and inflammation during therapy. The application is similar to the radiation oral mucositis application discussed below — the honey is held in the mouth, then slowly swallowed to coat the esophagus on its way down. Evidence is preliminary; supportive care for radiation esophagitis remains primarily proton pump inhibitor therapy plus analgesics.

Back to Table of Contents

Sore Throat and Pharyngitis

The traditional use of honey for sore throat goes back millennia — ancient Egyptian, Greek, and Roman medical texts all reference honey for throat conditions. The modern question is whether manuka honey offers any specific advantage over conventional honey or over commercial throat lozenges and demulcents.

The mechanism for sore throat benefit is partly antibacterial (against bacterial pharyngitis, particularly group A streptococcus) but primarily demulcent and anti-inflammatory. The viscous honey coats the inflamed pharyngeal mucosa, providing mechanical buffering against the irritation of swallowing and breathing. The osmotic action draws fluid out of the inflamed tissue, reducing edema. The MGO provides direct antibacterial activity against the surface bacterial colonization that contributes to ongoing inflammation.

For viral pharyngitis (the cause of 80-90% of acute sore throat in adults), the antibacterial action is not the primary mechanism — the demulcent and anti-inflammatory effects are. Manuka honey is reasonably substitutable with conventional honey in this application; the MGO is helpful but not essential for the demulcent effect. The advantage of manuka is the established antibacterial activity if bacterial pharyngitis is suspected, the standardization (UMF/MGO ratings), and the more potent overall therapeutic effect.

For streptococcal pharyngitis (strep throat, group A strep), manuka honey is an adjunct only — it does not replace antibiotic therapy (penicillin VK or amoxicillin) because strep throat requires systemic antibiotic to prevent rheumatic fever and other delayed sequelae. The role of manuka is symptomatic comfort and adjunctive antibacterial action.

Back to Table of Contents

Bardy 2008 — Radiation Oral Mucositis Trial

The most-rigorous mucositis trial of manuka honey was Bardy et al. (2008) in the British Journal of Oral and Maxillofacial Surgery. 131 patients receiving radical radiation therapy for head and neck cancer were randomized to active manuka honey (Comvita UMF 18+) or standard oral care, with primary endpoint of WHO mucositis grade at the end of radiation therapy. Results:

The trial was negative for primary endpoint but with mechanistic and quality-of-life signals worth noting. Subsequent trials have been mixed — some showing benefit on patient-reported outcomes, none showing dramatic effect on objective mucositis grade. The current state of evidence is that manuka honey is a reasonable adjunct to standard oral-care protocols for radiation oral mucositis, with modest patient-reported benefit and minimal downside, but not a primary preventive or therapeutic intervention.

The application protocol used in the Bardy trial: 20 mL manuka honey, held in mouth, gargled, swished, and finally swallowed, three times daily throughout the radiation course. This protocol is reasonable to extrapolate to other settings (chemotherapy mucositis, esophagitis, radiation laryngitis).

Back to Table of Contents

McLaughlin 2014 — Post-Tonsillectomy Lozenge

McLaughlin et al. (2014) in the Journal of Laryngology and Otology randomized 90 children and adults undergoing tonsillectomy to receive either manuka honey lozenges (Wedderspoon Organic 16+ formulation) or placebo lozenges for 10 days post-op, with primary endpoint of analgesic consumption. Results:

The trial demonstrates a useful adjunctive role for manuka honey lozenges in the post-tonsillectomy recovery period — not replacing analgesics, but reducing them during the prolonged tail of pain that follows surgery. The lozenge format provides extended mucosal contact time, which is more important for clinical effect than total honey dose.

The application extrapolates reasonably to other upper aerodigestive surgical procedures (uvulopalatopharyngoplasty for sleep apnea, adenotonsillectomy in children, oropharyngeal cancer resection) and to acute viral pharyngitis. Standard manuka honey lozenge dose is 1 lozenge every 2-4 hours as needed.

Back to Table of Contents

Cough — Cochrane Evidence in Children

Honey (not specifically manuka, but honey in general) has the strongest pediatric evidence of any cough remedy. The Cochrane 2018 review (Oduwole et al.) of honey for acute cough in children pooled 6 RCTs in 899 children, comparing honey to over-the-counter cough medicines (dextromethorphan, diphenhydramine), no treatment, or placebo. Results:

The Cochrane review specifically excluded children under 12 months due to infant botulism risk. The standard dose used across the trials was 1.5-5 mL (approximately half to one teaspoon) of honey given 30 minutes before bedtime.

The AAP and WHO both endorse honey as a first-line cough remedy in children over 12 months and explicitly recommend it in preference to over-the-counter cough medicines, which have been demonstrated to be no more effective than placebo and to carry pediatric safety concerns. Manuka honey is reasonable to use in this application, though the more expensive medical-grade product is not necessary — ordinary culinary honey works equally well for cough symptom relief, where the demulcent effect predominates over antibacterial activity.

Back to Table of Contents

Swallow vs Dissolve — Practical Application

The application technique matters for the desired clinical effect:

The "swallow versus dissolve" question depends on the target site of action. For pharyngeal and oral pathology, slow dissolution is preferred. For gastric pathology (H. pylori, gastric ulcer), direct ingestion with brief mouth holding is preferred. For combined applications, hold-and-swallow technique addresses both.

Back to Table of Contents

SIBO, IBS, and Gut Microbiome Considerations

Several patient questions arise about whether manuka honey's antibacterial activity translates to benefit for small intestinal bacterial overgrowth (SIBO), irritable bowel syndrome (IBS), or other gut microbiome conditions. The mechanistic answer is: probably not, with caveats.

As discussed above, MGO is largely inactivated by pancreatic secretions in the duodenum. Oral manuka honey does not deliver clinically meaningful antibacterial concentrations to the small intestine, colon, or beyond. SIBO, C. difficile colitis, ulcerative colitis flares, and other distal gut conditions are not addressed by oral manuka honey at any practical dose.

Conversely, the sugar load of honey (approximately 80% sugar, primarily fructose and glucose) can worsen SIBO symptoms in susceptible individuals — fructose is a known SIBO trigger food. Patients with SIBO who try manuka honey for any reason often experience bloating, gas, and increased symptoms within hours. For SIBO patients, manuka honey's antibacterial activity does not outweigh its fermentable sugar burden in the small intestine.

For IBS-D (diarrhea-predominant), the honey's osmotic effect can worsen diarrhea. For IBS-C (constipation-predominant), honey's mild laxative effect (from fructose malabsorption) may be helpful or counterproductive depending on the individual.

The exception is the use of manuka honey for upper-GI symptoms in IBS patients — sore throat from acid reflux, mild esophagitis, gastric discomfort. In these specific indications, the local action on the esophagus and stomach can be beneficial without the fermentable-sugar concerns of lower gut delivery.

For comprehensive SIBO management see our SIBO overview and SIBO root causes deep-dive.

Back to Table of Contents

Cautions — Including the Infant Botulism Warning

Back to Table of Contents

Key Research Papers

  1. Al Somal N, Coley KE, Molan PC, Hancock BM (1994). Susceptibility of Helicobacter pylori to the antibacterial activity of manuka honey. J R Soc Med, 87(1): 9-12. — PubMed
  2. McGovern DP, Abbas SZ, Vivian G, Dalton HR (1999). Manuka honey against Helicobacter pylori. J R Soc Med, 92(8): 439. — PubMed
  3. Bardy J et al. (2008). A systematic review of honey uses and its potential value within oncology care. J Clin Nurs, 17(19): 2604-23. — PubMed
  4. Bardy J, Molassiotis A, Slade D, Yates D, Brown S, Pilling M (2008). Active manuka honey and the prevention of radiation-induced oral mucositis: a double-blind randomized controlled trial. Eur J Cancer Care. — PubMed
  5. McLaughlin C, Casey J, Heaney B, Adair R (2014). Manuka honey lozenges in post-tonsillectomy pain management: a randomized controlled trial. J Laryngol Otol. — PubMed
  6. Oduwole O, Udoh EE, Oyo-Ita A, Meremikwu MM (2018). Honey for acute cough in children. Cochrane Database Syst Rev, 4: CD007094. — PubMed
  7. Paul IM, Beiler J, McMonagle A, Shaffer ML, Duda L, Berlin CM (2007). Effect of honey, dextromethorphan, and no treatment on nocturnal cough and sleep quality for coughing children and their parents. Arch Pediatr Adolesc Med. — PubMed
  8. Khanal B, Baliga M, Uppal N (2010). Effect of topical honey on limitation of radiation-induced oral mucositis: an intervention study. Int J Oral Maxillofac Surg. — PubMed
  9. Hawley P et al. (2014). A randomized placebo-controlled trial of manuka honey for radiation-induced oral mucositis. Support Care Cancer. — PubMed
  10. Manyi-Loh CE, Clarke AM, Munzhelele T, Green E, Mkwetshana NF, Ndip RN (2010). Selected South African honeys and their extracts possess in vitro anti-Helicobacter pylori activity. Arch Med Res. — PubMed
  11. Maddocks SE, Lopez MS, Rowlands RS, Cooper RA (2012). Manuka honey inhibits the development of Streptococcus pyogenes biofilms and causes reduced expression of two fibronectin binding proteins. Microbiology. — PubMed
  12. Brudzynski K (2006). Effect of hydrogen peroxide on antibacterial activities of Canadian honeys. Can J Microbiol. — PubMed

PubMed Topic Searches

Back to Table of Contents

Connections

Back to Table of Contents